TB-500

TB-500 is synthetic thymosin beta-4, a forty-three-residue actin-sequestering peptide studied in animal models of tissue repair and cell migration.

Yes. 11 third party certificates for TB-500 are published on this site, covering endotoxin, purity and sterility. Each one is the report as the testing laboratory issued it, not a retyped summary, and the most recent lot is 10mg · 3/12/2026. Match the batch on your vial to the batch on the report.

77591-33-4. It is printed in the specification table on this page so it can be checked against your own records before ordering.

Refrigerate (2-8 deg C) Lyophilized powder is the stable form; once reconstituted, a solution is far more fragile and should be aliquoted rather than repeatedly frozen and thawed.

>=99% by HPLC. The released figure for any given lot is on that lot's certificate rather than taken from this page, because purity is a property of a batch and not of a product line.

No. This is sold for laboratory research use only. It is not a drug, not a supplement, and not approved by the FDA for human or veterinary use. We do not provide dosing, administration, or protocol guidance, by phone, by email, or through the assistant on this site.

Not always. TB-500 is a research-market name that vendors apply to full-length synthetic thymosin beta-4 and, in some cases, to a shorter fragment containing the LKKTETQ actin-binding region. The two differ in mass, in reported activity profile, and in how published results apply. Confirm identity against the mass spectrometry data for the specific lot.

Topical ophthalmic formulations of synthetic thymosin beta-4 have been evaluated in registered randomized human trials, including a published phase 2 dry eye trial. There is no completed human clinical trial of the injectable research peptide for musculoskeletal or systemic applications, and the ophthalmic results do not transfer to other routes or tissues.

Because there is no tertiary structure to denature, lyophilization and reconstitution do not require a refolding step, and mild temperature excursions do not destroy a fold that does not exist. Degradation instead proceeds by backbone hydrolysis in solution and by oxidation of the single methionine residue, so the controls that matter are time in solution, temperature, and air exposure.

TB-500 is a naturally occurring forty-three residue protein with a confirmed intracellular biochemical function, studied for additional extracellular activities. BPC-157 is a fifteen residue synthetic fragment with no confirmed endogenous role, studied primarily through angiogenic receptor and focal adhesion signaling. TB-500 has a firmer biochemical foundation; both have animal-dominated repair literatures.

It is the central heptapeptide region most often identified as the actin-binding domain of thymosin beta-4. Several published studies use this fragment or extended versions of it instead of the full protein, which is one reason results reported for TB-500 in the literature are not always directly comparable.

Yes. TB-500 appears on the World Anti-Doping Agency Prohibited List under the category covering peptide hormones, growth factors, and related substances.